Drugs / SCAR02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06503224 | Apr 2024 → Apr 2026 overdue | autoimmune disease | The First Affiliated Hospital of University of Science and Technology of China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCAR02 | “An Exploratory Clinical Study of a Fourth-generation Autologous CAR-T Cell Injection (SCAR02) Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases” NCT06503224 ↗ |
| Modality | Cell therapy | “Fourth-generation Autologous CAR-T Cell Injection (SCAR02)” NCT06503224 ↗ |
| Route | Intravenous | “A single intravenous infusion of anti-BCMA and CD19 CART cells” NCT06503224 ↗ |